Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523237 · ClinicalTrials.gov registry record · NA
RAL-eve Study: Raltegravir Substitution Study
A NA study of HIV Infections, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00523237: Completed NA study of HIV Infections, sponsored by Stanford University.
NCT00523237 is a NA study of HIV Infections that has completed, run by Stanford University. The registered enrollment target is 14 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00523237, a NA study of HIV Infections, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to: * Provide raltegravir to subjects with HIV and an undetectable viral load who are experiencing injection site reactions (ISR) to Enfuvirtide, * Monitor the safety and efficacy of raltegravir, and * Assess the change in quality of life in patients who have switched from Enfuvirtide to raltegravir
Primary Outcome
evaluate the percent of patients with viral load of \<50 copies at week 24 of study after being switched from enfuvirtide to raltegravir
Conditions Studied
Interventions
- DRUG Raltegravir
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-12 |
| Phase | NA |
What the finished NCT00523237 record still lists
NCT00523237 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (97% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Raltegravir is the first listed.
NCT00523237 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00523237 about?
NCT00523237 is a clinical study titled "RAL-eve Study: Raltegravir Substitution Study". The purpose of this study is to: * Provide raltegravir to subjects with HIV and an undetectable viral load who are experiencing injection site reactions (ISR) to Enfuvirtide, * Monitor the safety and efficacy of raltegravir, and * Assess the change in quality of life in patients who have switched f...
What is the current status of trial NCT00523237?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2007-10. Estimated completion is 2010-12.
What conditions does trial NCT00523237 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00523237?
The interventions under investigation include: Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00523237?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00523237 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00523237's enrollment target sits among peer trials
14 514th of 542 higher than 26 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia